

## **Product** Data Sheet

# Sinapultide TFA

Cat. No.: HY-P2207A CAS No.: 2828433-25-4 Molecular Formula:  $C_{128}H_{239}F_3N_{26}O_{24}$ 

Molecular Weight: 2583.42

KLLLLKLLLKLLLK (TFA) Sequence Shortening: Target: **Biochemical Assay Reagents** 

Pathway: Others

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

### **BIOLOGICAL ACTIVITY**

Description	Sinapultide TFA is a 21-amino-acid peptide that mimics the action of human surfactant protein-B (SP-B). Sinapultide TFA can be used for synthetic phospholipids surfactants improvement $^{[1]}$ .
In Vitro	Sinapultide TFA microbubble preparation (2 $\mu$ g/mL, 5 $\mu$ g/mL; 24 h) combined with ultrasound (0.5 MHz, 40 s) could promote the function recovery of injured AT II cells effectively via affecting TNF- $\alpha$ and IL-6 levels <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Sinapultide TFA-loaded microbubbles (MBs) (0.1 mg; nasal delivery; collected at 3, 6, 12 and 24 hours after LPS) improves pulmonary edema in lung injury and increases lung W/D weight in LPS-induced ALI mice <sup>[2]</sup> .  MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### **REFERENCES**

[1]. Braide-Moncoeur O, et al. Peptide-based synthetic pulmonary surfactant for the treatment of respiratory distress disorders. Curr Opin Chem Biol. 2016 Jun;32:22-8.

[2]. Liu D, et al. Sinapultide TFA-Loaded Microbubbles Combined with Ultrasound to Attenuate Lipopolysaccharide-Induced Acute Lung Injury in Mice. Drug Des Devel Ther. 2020 Dec 22;14:5611-5622.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

**Screening Libraries** 

Inhibitors

**Proteins**